Payment overview · 2025
General Payments
$837.83
46 reported records · 17 companies
Healthcare provider profile · identity verified
Thomas Scott Rives, M.D.
Allopathic & Osteopathic Physicians|General Practice · LITTLE RIVER, SC · NPI 1457342370
Verified facts
What the public records show
CMS Open Payments records show Thomas Scott Rives, M.D. received $837.83 in general payments during 2025 across 46 reported records.
Novo Nordisk Inc accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $207.00 | 24.7% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $167.77 | 20.0% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.49 | 6.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.74 | 5.8% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.99 | 5.2% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $38.41 | 4.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.40 | 4.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.36 | 4.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.52 | 4.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.29 | 4.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.97 | 3.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.98 | 3.5% | 2 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $18.06 | 2.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.99 | 2.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.79 | 1.9% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $15.19 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.88 | 1.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $837.83 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $144.91 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $65.71 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.24 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $52.49 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $48.74 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $43.99 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $38.41 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.40 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.36 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.52 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.29 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.29 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.97 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.98 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.98 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.50 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.88 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $7.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 145 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 159 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
145 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
159 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 845 | 243 |
| Amlodipine Besylate | Amlodipine Besylate | 518 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 124 |
| Losartan Potassium | Losartan Potassium | 458 | 129 |
| Lisinopril | Lisinopril | 408 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 377 | 110 |
| Omeprazole | Omeprazole | 353 | 110 |
| Gabapentin | Gabapentin | 294 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 279 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 212 | 69 |
| Metformin Hcl Er | Metformin Hcl | 211 | 58 |
| Trazodone Hcl | Trazodone Hcl | 204 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 200 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 53 |
| Ezetimibe | Ezetimibe | 167 | 46 |
| Metformin Hcl | Metformin Hcl | 165 | 45 |
| Mounjaro | Tirzepatide | 159 | 27 |
| Valsartan | Valsartan | 159 | 47 |
| Furosemide | Furosemide | 156 | 45 |
| Farxiga | Dapagliflozin Propanediol | 145 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 38 |
| Allopurinol | Allopurinol | 133 | 36 |
| Alprazolam | Alprazolam | 133 | 31 |
| Simvastatin | Simvastatin | 132 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 57 |
| Alendronate Sodium | Alendronate Sodium | 130 | 39 |
| Prednisone | Prednisone | 128 | 97 |
| Carvedilol | Carvedilol | 126 | 38 |
| Montelukast Sodium | Montelukast Sodium | 119 | 32 |
| Bupropion Xl | Bupropion Hcl | 116 | 28 |
| Meloxicam | Meloxicam | 116 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 42 |
| Eliquis | Apixaban | 109 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 31 |
| Potassium Chloride | Potassium Chloride | 102 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 29 |
| Sertraline Hcl | Sertraline Hcl | 93 | 29 |
| Famotidine | Famotidine | 89 | 23 |
| Clonazepam | Clonazepam | 83 | 12 |
| Lorazepam | Lorazepam | 77 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 24 |
| Jardiance | Empagliflozin | 72 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 65 |
| Finasteride | Finasteride | 68 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 55 |
| Ipratropium Bromide | Ipratropium Bromide | 65 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 16 |
| Glimepiride | Glimepiride | 58 | 15 |
| Trulicity | Dulaglutide | 53 | 13 |
| Buspirone Hcl | Buspirone Hcl | 51 | 13 |
| Ozempic | Semaglutide | 51 | suppressed |
| Diazepam | Diazepam | 50 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 13 |
| Synthroid | Levothyroxine Sodium | 47 | 16 |
| Atenolol | Atenolol | 46 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 11 |
| Tramadol Hcl | Tramadol Hcl | 45 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 12 |
| Azithromycin | Azithromycin | 37 | 34 |
| Pregabalin | Pregabalin | 37 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 12 |
| Celecoxib | Celecoxib | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 11 |
| Estradiol | Estradiol | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 18 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 25 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | 11 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 19 |
| Tradjenta | Linagliptin | 22 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 12 |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Betamethasone Valerate | Betamethasone Valerate | 16 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Testosterone | Testosterone | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 15 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 14 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $837.83 · 46 records | Novo Nordisk Inc | AIRSUPRA, APTIMA, AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GLYCATE, GVOKE HYPOPEN, Korlym, LEQVIO, MOUNJARO, OTEZLA, Ozempic, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Rybelsus, THINPREP 2000 PROCESSOR, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error